Rivoceranib
Rivoceranib Phase 2
Elevar Therapeutics · Phase 2 · Terminated · Enrollment 80
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|---|---|---|---|---|
| Rivoceranib 700 mg | R/M ACC (n = 80; 72 evaluable) | 700 mg | Single arm | n/r | objective response rate (investigator): 15.3%, primary analysisobjective response rate (independent review): 9.7%, primary analysismedian progression-free survival: 9 months, primary analysismedian duration of response (investigator): 14.9 months, primary analysis |